

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

## NICE Technology Appraisal No. 211; Prucalopride for the treatment of chronic constipation in women

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Shire-Movetis (prucalopride)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Bladder and Bowel Foundation</li> <li>• Equalities National Council</li> <li>• Men's Health Forum</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• Pain UK</li> <li>• PromoCon</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The IBS Network</li> <li>• Wellbeing of Women</li> <li>• Women's Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Continence Advice</li> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• British Geriatrics Society</li> <li>• British Society of Gastroenterology</li> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• United Kingdom Clinical Pharmacy</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Abbot Laboratories UK (lactulose)</li> <li>• Actavis UK (glycerol suppositories)</li> <li>• Almirall (linaclotide)</li> <li>• Bio-Health (psyllium husk)</li> <li>• Boehringer Ingelheim (bisacodyl suppositories and tablets, docusate, macrogol, sodium picosulfate)</li> <li>• B R Pharmaceuticals (senna)</li> <li>• Cardinal Health Martindale Products (glycerol suppositories, bisacodyl suppositories)</li> <li>• Casen Fleet Laboratories (sodium dihydrogen phosphate dihydrate/disodium hydrogen phosphate dodecahydrate enema)</li> <li>• Chanelle Medical (biscodyl, macrogol)</li> </ul>

<p>Association</p> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Bromley CCG</li> <li>• NHS England</li> <li>• Powys Teaching Health Board</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Dr. Reddy's Laboratories UK (bisacodyl)</li> <li>• Forest Laboratories (phosphates enema, arachis oil enema, docusate enema)</li> <li>• Galen (macrogol, dantron, dantron/docusate sodium, senna)</li> <li>• Hermal (formerly Reckitt Benckiser) (ispaghula husk, glycerol suppositories, senna)</li> <li>• Intrapharm Laboratories (lactulose)</li> <li>• Kent Pharmaceuticals (glycerol suppositories, bisacodyl suppositories and tablets, lactulose, dantron, senna, dantron/docusate sodium)</li> <li>• Lanes Health (senna)</li> <li>• Manx healthcare (ispaghula husk)</li> <li>• Meda Pharmaceuticals (macrogol)</li> <li>• Merck Consumer Healthcare (senna)</li> <li>• Mylan (lactulose)</li> <li>• Napp Pharmaceuticals (dantron)</li> <li>• Norgine Pharmaceuticals (sterculia/frangula, macrogol, docusate sodium enema)</li> <li>• Novartis Consumer Health UK (lactulose, senna)</li> <li>• Perrigo (bisacodyl, senna)</li> <li>• Pinewood Healthcare (sodium citrate enema, dantron)</li> <li>• Potter's Herbal Medicines UK (psyllium husk, senna)</li> <li>• Procter &amp; Gamble Health and Beauty Care (ispaghula husk)</li> <li>• Sandoz (lactulose)</li> <li>• Solvay Healthcare (lactulose)</li> <li>• Teva UK (glycerol suppositories, lactulose, senna, dantron, docusate sodium)</li> <li>• Thornton &amp; Ross (glycerol suppositories, macrogol, magnesium hydroxide, senna)</li> <li>• Typharm (docusate)</li> <li>• UCB Pharma (sodium citrate enema, docusate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• CORE (Digestive Disorders Foundation)</li> <li>• Health Research Authority</li> <li>• MRC Clinical Trials Unit</li> </ul>
---	---

	<ul style="list-style-type: none"> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul>
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

**Definitions:****Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

**Commentators**

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

**Assessment group**

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.